---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-323940"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2026-07-29T20:35:16+00:00"
generated_at: "2026-07-29T20:36:13.846926+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics reports Q2 2026 net loss of $178.6M; BLA for z-rostudirsen accepted with Priority Review

## Summary
- Net loss of $178.6M ($1.08 per share) vs $110.9M ($0.97) in Q2 2025.
- BLA for z-rostudirsen (exon 51 DMD) accepted by FDA with Priority Review; PDUFA date Jan 21, 2027.
- Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for z-basivarsen in DM1; topline data Q1 2027.
- IND cleared for DYNE-302 in FSHD; Phase 1 trial planned.
- Cash, cash equivalents and marketable securities $898.5M as of June 30, 2026; expected cash runway into Q2 2028.

## SEC filing metadata
- accession: 0001193125-26-323940
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2026-07-29T20:35:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/0001193125-26-323940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-323940
- JSON: https://secwatch.observer/filing/0001193125-26-323940.json
- Plain text: https://secwatch.observer/filing/0001193125-26-323940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.